See the DrugPatentWatch profile for Rinvoq
Rinvoq's Current Status and Approvals
Rinvoq (upadacitinib) is an oral Janus kinase (JAK) inhibitor approved for several inflammatory conditions. Recent approvals include its use for adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers [1]. It is also approved for adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers [1]. Further, it has gained approval for moderate to severe atopic dermatitis in adults and adolescents 12 years and older whose disease is not adequately controlled with other medications [2].
When Does Rinvoq's Patent Exclusivity End?
The patent landscape for Rinvoq is complex, with various patents covering its composition of matter, manufacturing, and methods of use. DrugPatentWatch.com tracks these patents and their expiration timelines, which are crucial for understanding when generic or biosimilar competition might emerge [3]. For specific patent expiry dates related to Rinvoq's various indications and formulations, consulting resources like DrugPatentWatch.com is recommended [3].
How is Rinvoq Different from Other JAK Inhibitors?
Rinvoq is a selective JAK inhibitor, primarily targeting JAK1. This selectivity aims to differentiate it from other JAK inhibitors that may affect multiple JAK enzymes, potentially leading to a different safety and efficacy profile. Other JAK inhibitors include tofacitinib (Xeljanz), baricitinib (Olumiant), and filgotinib (Jyseleca) [4]. The specific JAK selectivity of each drug influences its therapeutic applications and associated risks.
What Are the Risks Associated with Rinvoq?
Rinvoq carries a boxed warning regarding serious infections, mortality, major cardiovascular events, thrombosis, and malignancies [1][2]. These risks are associated with the JAK inhibitor class as a whole. Patients are advised to discuss these potential risks with their healthcare providers.
What Clinical Data Supports Rinvoq's Approvals?
Approvals for Rinvoq are based on robust clinical trial data. For psoriatic arthritis and ankylosing spondylitis, studies like SELECT-PsA and SELECT-AXIS demonstrated significant improvements in disease activity and patient-reported outcomes [1]. For atopic dermatitis, trials such as Measure Up 1 and Measure Up 2, alongside other pivotal studies, showed efficacy in achieving skin clearance and reducing itch [2].
Who is Developing and Marketing Rinvoq?
Rinvoq is developed and marketed by AbbVie [1][2]. AbbVie is a global biopharmaceutical company with a portfolio of treatments across various therapeutic areas.